National Bank Of Canada Aeterna Zentaris Inc. Transaction History

National Bank Of Canada

  • $72.7 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022
BUY
$0.17 - $0.37 $0 - $0
1 Added 0.01%
11,904 $2,000
Q4 2021

Jan 24, 2022
BUY
$0.36 - $0.77 $4,285 - $9,165
11,903 New
11,903 $4,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email